Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación
Artículo científico (JournalArticle)
Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer
Immunotherapy has transformed the treatment of non-small cell lung cancer (NSCLC). Yet, acquired resistance
remains a major clinical challenge. Defining molecular determinants of tumor sensitivity to T cell-mediated
killing is therefore critical. Tumor necrosis factor α (TNF-α) released by cytotoxic T cells promotes tumor
cell death, whereas NF-κB signaling supports survival. Autophagy counteracts TNFα-induced apoptosis,
and its inhibition enhances responses to immune checkpoint inhibitors (ICIs). Genomic alterations further
contribute to immune evasion and reduced immunotherapy efficacy. We previously identified DSTYK, a
dual serine/threonine and tyrosine kinase amplified in NSCLC, as a suppressor of TNF-α-mediated CD8+
T cell killing and a driver of ICI resistance through autophagy. Here, we show that DSTYK modulates
TNFR1 signaling by phosphorylating the autophagy initiator ULK1, which enables ULK1-dependent phosphorylation
of RIPK1. Loss of DSTYK disrupts ULK1 activation, promotes RIPK1 autophosphorylation, proapoptotic
signaling, and impaired NF-κB-dependent survival. These findings define a DSTYK-ULK1-RIPK1
axis controlling TNF-α-induced apoptosis and support targeting ULK1 to sensitize DSTYK-amplified
NSCLC to T cell-mediated killing., FThis work was supported by FIMA, CIBERONC (CB16/12/00443), Fundación La Caixa, Spanish Ministry of Economy and Innovation, Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI22/00451 and PI23/00223), and the European Union Mission Cancer Program (SPACETIME and HORIZON-MISS-2023-CANCER-01). K.V. was supported by an investigator grant from the Asociación Española contra el cáncer (AECC) and a Ramón y Cajal contract; E.M. was supported by PFIS, Spanish Ministry of Health (ISCIII, Fondo de Investigación Sanitaria); C.V.-I. was supported by a Navarra Government predoctoral grant; D.O. was supported by FPU; and B.P. was supported by Zalain Jetetxea S.L., Conservas Martiko S.A., Ángel Cerdá S.L., and Nesucar S.L.